Corvidane

Developing a novel, safe drug to prevent heart attacks, strokes, and liver transplants from NASH

Print
Claim My Business
Form C
View on Wefunder
Security Type
Debt
Categories
Technology, Healthcare & Medical, Life Sciences, Community & Lifestyle
Min Investment
$100
Location
Brooklyn, NY
Offering Date
October 18, 2021
Expected Close Date
April 29, 2024
Target Raise
$50.00K-$618.00K
No. Investors
222
Security Price
$1
Website
corvidane.com
Number of Employees
3
Cash
$58,779
Revenue
$0
Short Term Debt
$549,807
Cost of Goods
$0
Long Term Debt
$0
Net Income
$-182,267

Company Description

Corvidane is developing Corvida™ to prevent the two leading causes of death worldwide and the leading cause of liver transplants in the United States.

Corvida™ is made of fatty acids, which are important dietary sources of fuel and they are structural components for cells.

Corvida™ uses Omega-7 and Omega-9 fatty acids for their ability to improve lipid metabolism and their anti-inflammatory properties.  This potential is used to target diseases of lipid metabolism and inflammation such as Atherosclerosis and NAFLD/NASH.

Key Deal Facts

CEO designed trials for Vascepa®, which reduces heart attack and stroke risk for high triglycerides.
Awarded $700k from Dutch government to perform more studies on our drug Corvida™'s potential.
Results of Corvida™'s affect on genes associated with atherosclerosis due in 2022.
Funds raised will lead to PreIND meetings with the FDA to ensure acceptability of human trials.
Corvida™'s components are designated GRAS (Generally Regarded as Safe) by the FDA.
Corvida™ is protected by patents in the US and Japan and are owned by the company.
This is an opportunity for you to impact global health and potentially realize significant financial gains.

Use of Proceeds

  • Operations 
  • Legal, accounting, market research
  • Manufacturing/CMC
  • Toxicology studies
  • Personnel 

Management Team / Advisory Board Bios

Paresh Soni, EO
20+ years of executive pharmaceutical experience in Cardiovascular diseases and NASH that includes Amarin, Alexion, Pfizer and Albireo. Led the NDA submission and approval of Vascepa®, designed and launched the landmark REDUCE-IT study.

Damion Boyer, Co-Founder / COO
6 years experience as CEO of Corvidane. Responsible for initiating Corvidane’s NASH program and forging strategic alliances in the U.S. and Europe, which includes UMC Utrecht and resulted in a non-dilutive subsidy from the Dutch government.

Peggy (Berry) Durst, VP of Regulatory
28 years of Regulatory experience that includes 5 years with Amarin. Developed and operationalized FDA Regulatory strategy for Vascepa®. Managed clinical trial submissions in the U.S., the EU and Canada.
Amount Raised : $356,713
Reveal the Score by Voting
＿
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
ⓘ
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
ⓘ
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
ⓘ
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
ⓘ
The value of the company compared to similar companies raising money from investors.
Valuation

Security Description

Debt is something, usually money, borrowed by one party from another. Debt is used by many corporations and individuals to make large purchases that they could not afford under normal circumstances. A debt arrangement gives the borrowing party permission to borrow money under the condition that it is to be paid back at a later date, usually with interest.

Research Reports

No reports have been submitted

Become a Reporter
Read Our Research Disclaimer

0 Comments

Post Comment